N,N,N',N''-Tetraethyl-guanidin | 45011-35-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N,N',N''-Tetraethyl-guanidin
• 英文别名: 1,1,2,3-Tetraethylguanidine
• CAS: 45011-35-6
• 化学式: C₉H₂₁N₃
• mdl: MFCD20617354
• 分子量: 171.286
• InChiKey: XUYQPZCEPGFBKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS ALPHA-CARBOXAMIDES
  申请人：CONVERGENCE PHARMACEUTICALS

  公开号：WO2011029762A1

  公开（公告）日：2011-03-17

  The present application provides a process for the preparation of α-carboxamide pyrrolidine derivatives of formula (I), wherein R1 and R2 are independently hydrogen, C1-6alkyl or C3-6cycloalkylC1-6alkyl; or such R1 and R2, together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R5 is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; either R6 or R7 is -O-R8, -OCHR9R8, -NCH2R8 or -(CH2)2R8 wherein the other R6 or R7 is hydrogen or R5; and wherein R8 is a phenyl ring or wherein the phenyl ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; and R9 is hydrogen or C1-3alkyl.

  本申请提供了一种制备式(I)的α-羧酰胺吡咯烷衍生物的过程，其中R1和R2分别是氢、C1-6烷基或C3-6环烷基C1-6烷基；或者这样的R1和R2，连同它们附着的氮，可以形成未取代的3、4、5或6-成员饱和环；X是碳或氮；n为0、1或2，当存在时，每个R5独立地从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中选择；R6或R7是-O-R8、-OCHR9R8、-N R8或-(CH2)2R8，另一个R6或R7是氢或R5；其中R8是苯环或苯环可以选择地由一个或多个独立选择的C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基基团取代；R9是氢或C1-3烷基。
• [EN] PURIFICATION OF PRAVASTATIN<br/>[FR] PURIFICATION DE LA PRAVASTATINE
  申请人：DSM IP ASSETS BV

  公开号：WO2009068556A1

  公开（公告）日：2009-06-04

  The present invention provides a method for the purification of pravastatin or a pharmacologically acceptable salt thereof by treating an aqueous solution comprising pravastatin with a nitrogen-containing base having a pKa value of 12 or higher. Furthermore, the present invention provides a composition comprising pravastatin sodium and 6-epi-pravastatin the quantity of which is 0.2% or less by weight of the composition and 3-α-isopravastatin the quantity of which is 0.2% or less by weight of the composition.

  本发明提供了一种通过将含普伐他汀的水溶液与pKa值为12或更高的含氮碱处理来纯化普伐他汀或其药理学上可接受的盐的方法。此外，本发明提供了一种组合物，包括普伐他汀钠和6-epi-普伐他汀，其重量占组合物的0.2%或更少，以及3-α-异普伐他汀，其重量占组合物的0.2%或更少。
• PROCESS FOR PREPARING BICYCLIC GUANIDINES
  申请人：WACKER CHEMIE AG

  公开号：US20210214367A1

  公开（公告）日：2021-07-15

  Bicyclic guanidines are prepared by reacting dialkylenetriamines with dialkylcarbonates in the presence of a silane of the formula Si(OR x ) o R Y (4−o) (IV) and/or their partial hydrolysates, with the proviso that contain minimally one unit IV which is a monovalent optionally substituted hydrocarbon radial with 3 to 10 carbon atoms.

  双环胍可通过在Si（ORx）oRY（4- o）（IV）的存在下，使用二烷基碳酸酯与二烷基三胺反应制备，并且/或它们的部分水解物，其中至少包含一个单位IV，该单位IV是具有3至10个碳原子的单价可选取代的碳氢基。
• Crystalline beta-lactam intermediate
  申请人：——

  公开号：US20020065262A1

  公开（公告）日：2002-05-30

  Crystalline 7-[2-(2-formylaminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid-1-(isopropoxycarbonyloxy)ethyl ester and its use.

  晶体化7-［2-（2-甲酰氨基噻唑-4-基）-2-（Z）-（甲氧肟）乙酰胺基］-3-甲氧甲基-3-头孢烷-4-羧酸-1-（异丙氧羰基氧）乙酯及其用途。
• PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES
  申请人：Zajac Matthew Allen

  公开号：US20120226053A1

  公开（公告）日：2012-09-06

  The present application provides a process for the preparation of α-carboxamide pyrrolidine derivatives of formula (I), wherein R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkylC 1-6 alkyl; or such R 1 and R 2 , together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R 5 is independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; either R 6 or R 7 is —O—R 8 , —OCHR 9 R 8 ,—NCH 2 R 8 or —(CH 2 ) 2 R 8 wherein the other R 6 or R 7 is hydrogen or R 5 ; and wherein R 8 is a phenyl ring or wherein the phenyl ring is optionally substituted by one or more groups independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; and R 9 is hydrogen or C 1-3 alkyl.

  本申请提供了一种制备式(I)的α-羧酰胺吡咯烷衍生物的方法，其中R1和R2分别为氢、C1-6烷基或C3-6环烷基C1-6烷基；或者这样的R1和R2，与它们连接的氮一起，可以形成未取代的3、4、5或6元饱和环；X为碳或氮；n为0、1或2，其中当存在时，每个R5都独立地选自C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表；R6或R7为—O—R8、—OCHR9R8、—N R8或—（CH2）2R8，其中另一个R6或R7为氢或R5；R8为苯环或苯环可选择地被一个或多个独立选自C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的基团取代；R9为氢或C1-3烷基。